Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
View Patent ↗The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
1. A pharmaceutical composition comprising:
a) a first pharmacologically active ingredient, which is selected from
and physiologically acceptable salts thereof, and
b) a second pharmacologically active ingredient, which is meloxicam or physiologically acceptable salts thereof,
wherein the pharmaceutical composition comprises the first pharmacologically active ingredient in a dose of from 10 to 800 μg and the second pharmacologically active ingredient in a dose of from 2 to 18 mg.
2. The pharmaceutical composition according to claim 1 , wherein the first pharmacologically active ingredient is
3. The pharmaceutical composition according to claim 2 , wherein the second pharmacologically active ingredient is meloxicam.
4. The pharmaceutical composition according to claim 1 , wherein the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient is within the range of from 1:2.5 to 1:1800.
5. A pharmaceutical dosage form comprising the pharmaceutical composition according to claim 1 .
6. The pharmaceutical dosage form according to claim 5 , which is for oral, intravenous, intraperitoneal, transdermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration.
7. The pharmaceutical dosage form according to claim 5 , which provides under in vitro conditions immediate release or controlled release of the first pharmacologically active ingredient and/or the second pharmacologically active ingredient.
8. A kit comprising a first pharmaceutical dosage form comprising the first pharmacologically active ingredient as defined in claim 1 and a second pharmaceutical dosage form comprising the second pharmacologically active ingredient as defined in claim 1 .
9. The kit according to claim 8 , wherein the first and the second pharmaceutical dosage form are adapted for simultaneous or sequential administration, either by the same or a different pathway of administration.